Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsIndependence Blue Cross Prior Auth & Coverage | Op…
    Ask Trek AI about this page
    CurrentIndependence Blue CrossPolicy N/A

    Prescription drug guidelines — coverage criteria for prior authorization, safety edits, and formulary exceptions

    Customize your policy alerts

    Sign up for all independence_blue_cross policy alerts

    Know when independence_blue_cross releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Rules and processes governing coverage, prior authorization, safety edits (age, quantity, MME, stimulant limits), formulary exceptions, and appeals for Independence Blue Cross prescription drug plans administered by a PBM. Applies to members of the Standard Formulary, Select Drug Program Formulary, and Value Formulary.

    Policy Summary
    PayerIndependence Blue Cross
    PolicyPrescription drug guidelines — prior authorization, safety edits, formulary exceptions
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit complete prior authorization requests via accepted ePA platforms, prior authorization form, or fax to avoid delays or denials.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2 business daysdecision time (once info complete)
    90 MME/dayopioid MME threshold
    3 alternativesmin. trial for non-formulary (Value)
    75% utilization

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    refill-too-soon threshold
    60–72 mg/dayexample stimulant limits

    Coverage and Prior Authorization Criteria

    Prior authorization and safety edits

    Coverage and approvals are contingent on meeting prior authorization criteria and safety edits as evaluated by PBM clinical pharmacists using P&T‑approved criteria.

    Prior Authorization Approval: Provider submits a complete prior authorization request via accepted channels (ePA platforms, prior authorization form, or letter of medical necessity); clinical criteria are met per Pharmacy & Therapeutics Committee–approved guidelines; no unresolved contraindications or safety edit failures (age limits, quantity limits, MME limit, cumulative stimulant limits); dosing and therapy history support medical necessity.see safety edits and thresholds (age limits, quantity limits, >=90 MME/day, agent-specific stimulant limits)

    Clinical pharmacists evaluate requests and may escalate to a medical director if criteria are not met or ambiguous. Incomplete information will delay or may lead to denial; typical decision time is up to 2 business days once complete information is received.

    Formulary exception

    Formulary exception requests are considered when specific conditions are met.

    Non-Formulary Exception (Value Formulary): Provider documents a trial of at least three formulary alternatives when available OR documents a contraindication to formulary alternatives; completes and submits a non-formulary exception request form with supporting rationale to the PBM.trial of >=3 formulary alternatives when available

    If approved, the drug is covered at the highest applicable cost-sharing and safety edits (quantity limits, MME and stimulant limits, age limits) still apply.

    Coverage for prescriptions that fall outside FDA age guidelines requires prior authorization. Safety edits include age limits; if a prescribed drug is not approved for the member’s age (for example, some agents are FDA‑approved only for individuals age five and older), coverage may be denied until an override is requested and approved. Prescribers may request an age‑limit override when medically necessary. Approval criteria for age‑limit reviews were developed and approved by the Pharmacy and Therapeutics Committee, and providers should initiate prior authorization per the plan’s submission processes.

    Prescriptions that fall outside FDA‑approved use or accepted clinical indications may be denied unless a prior authorization supporting medical necessity is submitted and approved. Safety edits are applied to align coverage with FDA labeling and clinical practice guidelines; when a drug’s use is off‑label or otherwise not consistent with these standards, the prescriber must provide documentation during the prior authorization process to justify the clinical use. If the documentation does not demonstrate medical necessity, coverage may be withheld.

    Dose Limits and Coding Thresholds

    High cumulative daily stimulant dose — agent examples/limits
    Amphetamine (includes Adzenys, Dyanavel, Evekeo)Limit = 60 mg/day
    Amphetamine/Dextroamphetamine (e.g., Adderall, Mydayis)Limit = 60 mg/day
    Dextroamphetamine (e.g., Dexedrine, Zenzedi, ProCentra, Xelstrym)Limit = 60 mg/day
    Lisdexamfetamine (Vyvanse)Limit = 70 mg/day
    Dexmethylphenidate (Focalin IR/XR)Limit = 40 mg/day
    Methylphenidate (Concerta, Ritalin, others)Limit = 72 mg/day
    Opioid cumulative MME limit (trigger threshold)

    What Providers Must Do

    Prior Authorization

    Prior authorization required for select drugs

    Independence Blue Cross requires prior authorization for certain covered drugs to confirm medical necessity and appropriate use; PBM clinical pharmacists evaluate requests using Pharmacy & Therapeutics Committee–approved criteria and may escalate to a medical director.

    Step Therapy

    Formulary exception requires trial of ≥3 formulary alternatives

    For Value Formulary members, a non‑formulary (formulary exception) request generally requires documentation of a trial of at least three formulary alternatives when available, or documentation of contraindications to those alternatives.

    • Complete and fax the non‑formulary exception request form to 1-888-671-5285 with supporting rationale.
    • If approved, coverage is at the highest applicable cost‑sharing and safety edits (e.g., quantity limits, MME) still apply.

    Background and Rationale

    Safety edits are applied to promote safe, appropriate medication use and to align coverage with FDA labeling and clinical guidelines. Key safety edits include age limits (drugs outside FDA age recommendations require prior authorization or an override request), quantity limits (set according to FDA‑approved maximum daily doses, standard dosing, and length of therapy), and cumulative dose thresholds such as opioid MME limits and high cumulative stimulant dose checks. These edits are evaluated by PBM clinical pharmacists using Pharmacy & Therapeutics Committee–approved criteria and may prompt counseling at point of sale, prior authorization review, or escalation to a medical director when necessary.

    Key Definitions

    Prior authorization definition
    DefinitionPrior authorization means the prescribing doctor must obtain approval from the health plan to confirm the medication is medically necessary and appropriate before coverage
    PurposeTo confirm clinical appropriateness, FDA-labeled or medically accepted use, dosing, therapy history, and to review for interactions/contraindications
    Decision timeThe prior authorization process may take up to two business days once complete information is received; incomplete information will delay the decision
    MME definition
    DefinitionMorphine Milligram Equivalent (MME) is a standardized measure of opioid dose used to calculate cumulative daily opioid exposure for safety limits
    Use in policyMME is used to apply a cumulative daily limit (90 MME/day) across all opioid medications to determine need for prior authorization

    Initial Therapy Quantity and Safety Limits

    Quantity limits — initial therapy criteria

    Quantity limits are applied at initiation and maintenance to align dispensing with FDA‑approved dosing, standard dosing, and safety edits.

    Quantity limit types: Quantity over time, maximum daily dose, refill-too-soon, and day‑supply limits may apply depending on drug class and formulation.examples provided per drug class (see specific drug limits)

    Provider must request a quantity limit override via prior authorization for quantities beyond the listed limits.

    Quantity over time examples: Examples include Ibandronate 150 mg = 1 tablet per 30 days; Sumatriptan 50 mg = 18 tablets per 30 days; Blood glucose test strips = 200 strips per 30 days; Sildenafil and all oral ED agents = 8 tablets per 30 days (cumulative).per 30 days or as noted

    These limits prevent dispensing of excessive quantities by looking back over the rolling time period.

    Continuation and Renewal Criteria

    Continuation/renewal — approval duration and conditions

    Prior authorizations and formulary exceptions may be approved for a limited duration; renewal requires action by the provider.

    Renewal requirement: If approval is time‑limited (up to 2 years), the approval expiration date will be provided at time of approval; the provider must submit a new prior authorization request upon or before expiration to continue coverage.approval expiration date provided at time of approval (up to 2 years)

    Provider should submit renewal requests prior to expiration to maintain coverage; PBM clinical pharmacists will review renewal requests per established criteria.

    Step Therapy Requirements

    RequirementDetails
    Step-therapy requirement for Value Formulary members
    Providers must document trial and failure of at least three formulary alternatives when available, OR document contraindications to those formulary alternatives.
    How to request a non‑formulary exception
    Complete and fax a non‑formulary exception request form with supporting rationale to 1-888-671-5285.
    Coverage and edits if approved
    If approved, the non‑formulary drug is paid at the highest applicable cost‑sharing; safety edits such as quantity limits and MME limits still apply.
    If denied
    Member and provider will receive a denial letter including appeals language.

    Specific Quantity Limits (per fill/unit)

    Ibandronate 150 mg — 1 tablet
    DrugIbandronate 150 mg (generic for Boniva)
    Quantity limit1 tablet per 30 days
    Limit typeQuantity over time (30-day rolling period)
    Sumatriptan 50 mg — 18 tablets
    DrugSumatriptan 50 mg (generic for Imitrex)
    Quantity limit18 tablets per 30 days
    Limit typeQuantity over time (30-day rolling period)
    Policy Summary
    PayerIndependence Blue Cross
    PolicyPrescription drug guidelines — prior authorization, safety edits, formulary exceptions
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit complete prior authorization requests via accepted ePA platforms, prior authorization form, or fax to avoid delays or denials.
    SourceLink
    On This Page
    Coverage and Prior Authorization CriteriaDose Limits and Coding ThresholdsWhat Providers Must DoBackground and RationaleKey DefinitionsInitial Therapy Quantity and Safety LimitsContinuation and Renewal CriteriaStep Therapy RequirementsSpecific Quantity Limits (per fill/unit)
    Opioid cumulative daily MME triggerPrior authorization required when cumulative opioid dose ≥ 90 MME/day
    ScopeApplies across all opioids, calculated using total daily dose (single agent or combination)
    Examples of impacted opioidsIncludes morphine, oxycodone, hydrocodone, fentanyl, methadone, tramadol, others listed in the policy
    Note

    How to submit prior authorization

    Submit prior authorization requests via accepted ePA platforms (e.g., CoverMyMeds, SureScripts), by completing a prior authorization form, or by sending a letter of medical necessity; fax submissions are accepted at 1-888-671-5285.

    • PBM will notify the prescribing doctor of approvals or denials by fax, telephone, or letter.
    • If clinical pharmacists cannot approve based on criteria, the request will be reviewed by a medical director.
    Denial Risk

    Incomplete prior authorization information delays or risks denial

    Incomplete information on a prior authorization request will delay the decision and can result in delayed approval or denial; decisions take up to two business days once complete information is received.

    • Provide complete clinical data, dosing and therapy history, and any supporting documentation to avoid delays.
    • Incomplete submissions may trigger escalation or denial and prolong member notification.
    Calculation noteLimit is based on total daily dose of opioid drug by itself or in combination with other opioids
    Maximum daily dose examples: Examples include sedative hypnotics (zolpidem) = 1 tablet per day; oxycodone/acetaminophen 5/325 mg = 12 tablets per day; Guanfacine ER = 1 tablet per day.per day

    Maximum daily dose limits are based on FDA‑approved maximum daily dose and formulation.

    Refill and day‑supply limits: Refill‑too‑soon edits allow refill at 75% utilization; claims system evaluates supply on hand over prior 365 days and may reject if excess supply exists (e.g., >18 days on hand for a 30‑day fill).75% utilization / >18 days supply on hand for 30‑day fill

    Day supply limits apply for certain classes (e.g., opioids, butalbital) and may set shorter allowable day supplies for minors; quantity limit override required for exceedance.

    Blood glucose test strips — 200 strips
    ItemBlood glucose test strips (diabetic supplies)
    Quantity limit200 strips per 30 days
    Limit typeQuantity over time (30-day rolling period)
    Sildenafil and all oral ED agents — 8 tablets
    Drug classSildenafil and all oral erectile dysfunction agents (includes generic Viagra)
    Quantity limit8 tablets per 30 days (cumulative across all oral ED agents)
    Limit typeQuantity over time (30-day rolling period); cumulative across agents
    Zolpidem (sedative hypnotics) — 1 tablet
    Drug classSedative hypnotic drugs (example: zolpidem, generic for Ambien)
    Quantity limit1 tablet per day
    Limit typeMaximum daily dose
    Oxycodone/acetaminophen 5/325 mg — 12 tablets
    DrugOxycodone/acetaminophen 5/325 mg (generic for Percocet)
    Quantity limit12 tablets per day
    Limit typeMaximum daily dose
    Guanfacine ER — 1 tablet
    DrugGuanfacine ER
    Quantity limit1 tablet per day
    Limit typeMaximum daily dose (24-hour formulation)